Alzheimer’s disease is not a disease to wait on. The earlier, the better. Dr. Bredesen advises people as young as 45 years of age to request a baseline test from their physician that examines cognitive health, biochemistry, and genetics.
Dr. Bredesen has released a follow-up study to his 2014 publication, which first introduced a personalized, programmatic approach to combat cognitive decline in individuals displaying varying degrees of memory loss associated with SCI, MCI, and early Alzheimer’s disease. (more…)
Dr. Dale Bredesen and his laboratory colleagues have been working on understanding the most fundamental aspects of neurodegenerative illness for twenty-seven years. Dr. Bredesen trained at University of California, San Francisco, California Institute of Technology, Massachusetts Institute of Technology, and Duke University School of Medicine.